FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma
FRONTIER-3:一项随机 IIa 期研究,旨在研究托佐拉单抗(一种抗白介素-33 单克隆抗体)治疗早发性哮喘的疗效
期刊:Erj Open Research
影响因子:4
doi:10.1183/23120541.00183-2025
Corren, Jonathan; Reid, Fred; Moate, Rachel; Jimenez, Eulalia; Sadiq, Muhammad Waqas; Williams, Adam; Rytelewski, Mateusz; Cameron-Christie, Sophia; Muthas, Daniel; Georgi, Benjamin; Brooks, Dennis; Lindqvist, Eva; Kell, Chris; Platt, Adam; Belvisi, Maria G; Pandya, Hitesh